Literature DB >> 2231073

The costs of prevention.

M C Weinstein1.   

Abstract

A prevention program is cost-effective if it yields more health benefits than do alternative uses of health care resources. Some prevention programs meet this standard: either they actually save more health care resources than they utilize, or their net costs per healthy year of life gained are lower than those of alternatives such as curative or palliative medicine. Other prevention programs, however, are less cost-effective than are medical treatments for the same disease. One lesson for public policy is that generalizations about the cost-effectiveness of "prevention" are unwise. Another lesson is that prevention programs should not be subjected to a higher standard than other health programs: they should not be expected to save money, but they should be expected to yield improved health at a reasonable price.

Mesh:

Year:  1990        PMID: 2231073     DOI: 10.1007/bf02600850

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  5 in total

1.  A cost-effectiveness analysis of exercise as a health promotion activity.

Authors:  E I Hatziandreu; J P Koplan; M C Weinstein; C J Caspersen; K E Warner
Journal:  Am J Public Health       Date:  1988-11       Impact factor: 9.308

2.  Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction.

Authors:  L Goldman; S T Sia; E F Cook; J D Rutherford; M C Weinstein
Journal:  N Engl J Med       Date:  1988-07-21       Impact factor: 91.245

3.  Cost-effectiveness of interventions to prevent or treat coronary heart disease.

Authors:  M C Weinstein; W B Stason
Journal:  Annu Rev Public Health       Date:  1985       Impact factor: 21.981

4.  Foundations of cost-effectiveness analysis for health and medical practices.

Authors:  M C Weinstein; W B Stason
Journal:  N Engl J Med       Date:  1977-03-31       Impact factor: 91.245

5.  Cost-effectiveness of coronary artery bypass surgery.

Authors:  M C Weinstein; W B Stason
Journal:  Circulation       Date:  1982-11       Impact factor: 29.690

  5 in total
  9 in total

1.  Cost-effectiveness of new tests to diagnose and treat coronary heart disease.

Authors:  Leslee J Shaw; Allen J Taylor; Patrick G O'Malley
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-08

Review 2.  Primordial prevention, developing countries and the epidemiological transition: thirty years later.

Authors:  Sorin Ursoniu
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

3.  Treating cutaneous aging with patented technologies.

Authors:  Wing-Fu Lai; Marie C Lin
Journal:  J Biosci       Date:  2015-06       Impact factor: 1.826

4.  The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC).

Authors:  William H Herman; Barbara H Braffett; Shihchen Kuo; Joyce M Lee; Michael Brandle; Alan M Jacobson; Lisa A Prosser; John M Lachin
Journal:  J Diabetes Complications       Date:  2018-06-12       Impact factor: 2.852

5.  Economic evaluation of immunoprophylaxis in children with recurrent ear, nose and throat infections.

Authors:  K Banz; D Schwicker; A M Thomas
Journal:  Pharmacoeconomics       Date:  1994-11       Impact factor: 4.981

6.  Cost effectiveness of immunoprophylaxis in the prevention of recurrent infectious rhinitis in adults.

Authors:  G Berdeaux; A Lafuma; A M Perruchet; F Fagnani
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

7.  The financial implications of availability and quality of a usual source of care for children with special health care needs.

Authors:  Chia-Ling Liu; Alan M Zaslavsky; Michael L Ganz; James Perrin; Steven Gortmaker; Marie C McCormick
Journal:  Matern Child Health J       Date:  2007-06-08

8.  What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?

Authors:  William H Herman; Barbara H Braffett; Shihchen Kuo; Joyce M Lee; Michael Brandle; Alan M Jacobson; Lisa A Prosser; John M Lachin
Journal:  J Diabetes Complications       Date:  2018-06-12       Impact factor: 2.852

9.  Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France.

Authors:  Stéphanie Payet; Philippe Denis; Gilles Berdeaux; Robert Launois
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.